ARPA-H taps 7 teams for up to $160M to build bespoke gene editing drugs, betting on Baby KJ's playbook — but some scientists say funding falls short.
July 9, 2026 03:20 PM EDT
R&DCell/Gene Tx
ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?
Ryan Cross
Senior Science Correspondent
ARPA-H launches $160 million effort to develop custom gene editing drugs
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
Children's Hospital of Philadelphia Secures Five-year, up to $38.9 Million ARPA‑H Award to Advance Personalized Gene Editing Therapies
Roche ends Huntington's gene-silencing programs
The Jackson Laboratory, with the Broad Institute and Partners, Selected for ARPA-H THRIVE Award to Advance Gene Editing Platform for Pediatric Epilepsies and Rare CNS Diseases
Why a gene-editing breakthrough has some experts worried | CNN
Prime wins Beam arbitration, clearing path to clinic
An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs will…
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival…
Children's Hospital of Philadelphia Secures Five-year, up to $38.9 Million ARPA‑H Award to Advance Personalized Gene Editing…
The FDA, while promising flexibility in approving Baby KJ-type gene editing, still has set standards difficult for a small…
Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new…
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
